Earnings ·
Nyxoah SA reported second quarter and first half 2026 financial results, securing $110 million in aggregate financing…
NYXHNyxoah SA
Nyxoah SA reported second quarter and first half 2026 financial results, securing $110 million in aggregate financing during Q2. Global net revenue reached €7.7 million in Q2, a 21% sequential increase, bringing H1 2026 total to €14.0 million compared to €2.4 million in the prior year period. U.S. commercial momentum drove a 22% sequential growth in U.S. net revenue to €5.2 million. The company activated 89 new high-volume accounts and trained 55 additional surgeons, resulting in 180 active accounts and 427 patients under prior authorization entering Q3. Cash and cash equivalents plus financial assets totaled €97.8 million at June 30, 2026. Nyxoah operates in the medical technology industry, developing and commercializing innovative solutions to treat Obstructive Sleep Apnea.